Smilax Laboratories - Due diligence report

A 360° intelligence report on Smilax Laboratories: trust score, financial health, credit view, compliance, directors, growth and distress si…

2004-10-20 Hyderabad, Telangana Active Unlisted Active Compliant
Share
Connect MCP
SL Smilax Laboratories
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Smilax Laboratories — 360° Intelligence Report

Generated from MCA filings & public records
66/100
Trust Score
Moderate

Smilax Laboratories is assessed as Moderate with a Trust Score of 66/100. Smilax Laboratories is an active public limited indian non-government company incorporated in 2004, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and high financial risk profile.

Report generated on 02 Oct 2026 from the latest processed filings. Smilax Laboratories Limited snapshot & full profile →

Financial Health › Weak
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Good

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
66/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
66/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
30/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
45/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
60/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Externally credit-rated (BB+).

Charges position: 1 open (11.51 cr) · 8 satisfied (465.93 cr).

Banking relationships (from registered charges)
LenderChargesAmount
State Bank Of India2 48.0 cr
Idfc Limited2 48.0 cr
Axis Bank Limited2 48.0 cr
Andhra Bank1 48.0 cr
Bank Of India1 48.0 cr
Development Credit Bank Limited1 48.0 cr
Compliance Score: 66/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2025).
  • Litigation present in 2 court forum(s).
  • Delayed payments to MSME suppliers disclosed (11 disclosure(s)).
  • 3 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
RAMAKRISHNA REDDY MUNNAMGI 01234567 Director 01/04/2018 6 yrs Approved
SURYADEVARA MURALI KRISHNA 01234567 Director 01/04/2018 6 yrs Approved
PULICHERLA GANESH 01234567 Director 01/04/2018 6 yrs Approved
SURENDER REDDY GEEDIPALLI 01234567 Director 01/04/2018 6 yrs Approved
SAIBABA REDDY EADALA 01234567 Director 01/04/2018 6 yrs Approved
Radhika Jhawar 01234567 Director 01/04/2018 6 yrs Approved
  • 6 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2025)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2025 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
4 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: SURYADEVARA MURALI KRISHNA (Managing Director) · PULICHERLA GANESH (CFO)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 45 · Distress 60
Growth signals & trust indicators
EPFO headcount growing - hiring signal.
Operating for 21+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
1 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 1.86 cr.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence64/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment46/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 11.51 cr already registered.
  • Compliance gaps should be priced into terms.
Investor view45/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
12 Sep 2025
Last AGM held
Annual general meeting
10 Jun 2025
Director appointed
Radhika Jhawar (Company Secretary)
31 Mar 2025
Latest balance sheet
Filed with ROC
04 Sep 2023
Charge satisfied
Axis Bank Limited
15 Nov 2021
Director appointed
PULICHERLA GANESH (CFO)
20 Oct 2021
Director ceased
SURENDER REDDY GEEDIPALLI
Director ceased
SAIBABA REDDY EADALA
24 Sep 2021
Director appointed
SURENDER REDDY GEEDIPALLI (Director)
Director appointed
SAIBABA REDDY EADALA (Director)
Director ceased
BHAVANAM MASTAN REDDY
Director ceased
VULLANGULA SIVA PRASAD
18 May 2021
Charge satisfied
Axis Bank Limited
09 Oct 2020
Charge satisfied
State Bank Of India
20 Sep 2019
Director ceased
RAMAKRISHNA REDDY MUNNAMGI
25 Jun 2019
Director appointed
RAMAKRISHNA REDDY MUNNAMGI (Director)
10

Key Observations

Auto-generated from the data above
Revenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - leverage worth monitoring.
Net worth is positive.
6 active director(s) / partner(s); board looks stable and experienced.
3 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of BB+ from Care.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 4 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Eskag Sanjeevani U24234WB1977PTC030897 Kolkata, West Bengal, India
Amol Pharma U24230RJ1996PTC097657 Jaipur, Rajasthan, India
Swiss Garniers Biotech Private Limited U24304HP2018PTC007608 Mehatpur, Himachal Pradesh, India
Vasu Healthcare U24231GJ1980PTC003679 Baroda, Gujarat, India
Ideal Cures U24239MH1988PTC048150 Mumbai, Maharashtra, India
Sauravchemicals U24112PB1993PLC014017 Punjab, Punjab, India
Mepro Pharmaceuticals Private Limited U24231GJ1982PTC005451 Surendra Nagar, Gujarat, India
Sil L24219HR1993PLC032195 Haryana, Haryana, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Smilax Laboratories before audits and certifications: compliance score 66/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Smilax Laboratories: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 45/100, margin trends, ownership structure and peer set for Smilax Laboratories - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 66/100, distress signals and MSME payment-delay disclosures - know whether Smilax Laboratories pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Smilax Laboratories - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Smilax Laboratories an active company?

Smilax Laboratories has MCA status “Active” with a compliance score of 66/100 (Moderate).

Is Smilax Laboratories financially healthy?

Smilax Laboratories has a Financial Health Score of 30/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Smilax Laboratories?

Its overall Trust Score is 66/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Smilax Laboratories?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 6 active director(s) are on record.

Does Smilax Laboratories have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 8 earlier charge(s) stand satisfied.

Is Smilax Laboratories up to date with its ROC filings?

Balance sheet slightly behind (Mar 2025). Overall compliance score: 66/100 (Moderate).

Is it risky to lend to Smilax Laboratories?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.